StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Noxafil (posaconazole, legacy) by Quarter

Noxafil (posaconazole, legacy) — International sales ($M) ($M)

QuarterlyAnnual

Merck Noxafil (posaconazole, legacy): $37M in Q4 2024, down 14.0% from a year earlier. That is the lowest of the 33 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
37
Period ended Dec 31, 2024
Change on a year earlier
-14.0%
43 in Q4 2023
History
33 quarters
Since Q4 2016
Sources
24
Documents cited below

Where the Q4 2024 figure comes from

“|| Noxafil | 36 | 46 | -23 | -2 | 4 | -149 | 37 | 43 | -12”

Source: Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNoxafil (posaconazole, legacy) — International sales ($M) ($M)Year on yearSource
Q4 2024Dec 31, 202437-14.0%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202440-14.9%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 202444-2.2%Form 10-Q (filed 2024-08-05) ↗
Q1 2024Mar 31, 202448+4.3%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202343-6.5%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202347-4.1%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 2023450.0%Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 202346-4.2%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202246-8.0%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202249+8.9%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2022Jun 30, 202245-13.5%Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2022Mar 31, 202248-7.7%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 202150-25.4%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 202145-31.8%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 202152-22.4%Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2021Mar 31, 202152-40.2%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗

Breakdown

What makes up noxafil (posaconazole, legacy)

Cite this data

StockData. (2026). Merck Noxafil (posaconazole, legacy) ($M), quarterly Q4 2016–Q4 2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-noxafil-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.